Topics

High-grade gliomas | Treatment | Immunotherapy | CAR-T-Cells

Home > Publications > Topics > High-grade gliomas > Treatment > Immunotherapy > CAR-T-Cells

Gallus M, Young JS, Cook Quackenbush S, Khasraw M, de Groot J, Okada H.
Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations.
Neuro Oncol. 2024 Oct 24:noae203. doi: 10.1093/neuonc/noae203. PMID: 39450490. Review. ˍ

Grewal EP, Nahed BV, Carter BS, Gerstner ER, Curry WT, Maus MV, Choi BD.
Clinical progress in the development of CAR T cells to treat malignant glioma.
J Neurooncol. 2024 Dec 18. doi: 10.1007/s11060-024-04909-7. PMID: 39695004. Interventional; Review˰ ˍ

Park S, Maus MV, Choi BD.
CAR-T cell therapy for the treatment of adult high-grade gliomas.
NPJ Precis Oncol. 2024 Dec 19;8(1):279. doi: 10.1038/s41698-024-00753-0. PMID: 39702579. Review. ˍ

**Gu J, Li J, Xu Y, Zhang G, Xie J, Jia R, Chen W, Lu Z, Chang C, Wen H, Chang LJ, Ma H, Cai Q.
Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas.
J Transl Med. 2025 May 27;23(1):591. doi: 10.1186/s12967-025-06523-1. PMID: 40420236. Interventional study. ˍ